ReviewCancers2022
Review of the Standard and Advanced Screening, Staging Systems and Treatment Modalities for Cervical Cancer.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 53 citations in OpenAlex.
- miR-1307-3p promotes the progression of cervical cancer by targeting FOXO3.Irish journal of medical science · 2026Article
- Reprogramming the tumor immune microenvironment in cervical cancer: synergy between radiotherapy and immunotherapy.Molecular cancer · 2026Review
- Self-collection for primary HPV screening using dry swabs: a review of clinical performance, laboratory considerations, and patient preferences.Journal of clinical microbiology · 2026Review
- Article
- TSPOAP1-AS1: A Novel Biomarker for the Prognosis and Therapeutic Target in Cervical Cancer.Combinatorial chemistry & high throughput screening · 2026Article
- The application of liquid biopsy techniques in cervical cancer diagnosis, prediction and therapeutic surveillance.Journal of gynecologic oncology · 2025Review
- MicroRNA-1303 in cancer pathogenesis and therapy: clinical implications for biomarker development and targeted treatment strategies.Cancer cell international · 2025Review
- Article
- Inhibitory effects of tetraselmis algae extract on cervical cancer cell proliferation: a molecular and cellular approach.Molecular biology reports · 2025Article
- Exosomal miRNA-based theranostics in cervical cancer: bridging diagnostics and therapy.Medical oncology (Northwood, London, England) · 2025Review
- Quinalizarin induces autophagy, apoptosis and mitotic catastrophe in cervical and prostate cancer cells.Scientific reports · 2025Article
- Efficacy of integrating surgical interventions with chemoradiotherapy in managing stage IIIC cervical cancer.American journal of translational research · 2025Article
- Innovative Noninvasive HPV Screening Using a Feminine Pad: A Pilot Study for Enhanced Cervical Cancer Detection.Obstetrics and gynecology international · 2025Article
- Sociodemographic and clinical factors associated with delayed diagnosis of cervical cancer: a cross-sectional study, Brazil, 2016-2020.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2025Article
- Exploring MPC1 as a potential ferroptosis-linked biomarker in the cervical cancer tumor microenvironment: a comprehensive analysis.BMC cancer · 2024Article
- A visualization analysis of hotspots and global trends on pelvic floor dysfunction in cervical cancer.Journal of cancer research and clinical oncology · 2024Article
- Portable, and ultrasensitive HR-HPV tests based on nucleic acid biosensors.Frontiers in cellular and infection microbiology · 2024Review
- Development of Enzymatic Recombinase Amplification Assays for the Rapid Visual Detection of HPV16/18.Journal of microbiology and biotechnology · 2023Article
- 25-Hydroxycholecalciferol Inhibits Cell Growth and Induces Apoptosis in SiHa Cervical Cells via Autocrine Vitamin D Metabolism.Biomedicines · 2023Article
- hsa-mir-133a-2 promotes the proliferation and invasion of cervical cancer cells by targeting the LAMB3-mediated PI3K/ATK pathway.Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer arising from the uterine cervix is the fourth most common cause of cancer death among women worldwide. Almost 90% of cervical cancer mortality has occurred in low- and middle-income countries. One of the major aetiologies contributing to cervical cancer is the persistent infection by the cancer-causing types of the human papillomavirus. The disease is preventable if the premalignant lesion is detected early and managed effectively. In this review, we outlined the standard guidelines that have been introduced and implemented worldwide for decades, including the cytology, the HPV detection and genotyping, and the immunostaining of surrogate markers. In addition, the staging system used to classify the premalignancy and malignancy of the uterine cervix, as well as the safety and efficacy of the various treatment modalities in clinical trials for cervical cancers, are also discussed. In this millennial world, the advancements in computer-aided technology, including robotic modules and artificial intelligence (AI), are also incorporated into the screening, diagnostic, and treatment platforms. These innovations reduce the dependence on specialists and technologists, as well as the work burden and time incurred for sample processing. However, concerns over the practicality of these advancements remain, due to the high cost, lack of flexibility, and the judgment of a trained professional that is currently not replaceable by a machine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.